A man has a blood test taken to screen for prostate cancer at Parliament House in Canberra, Nov. 16, 2023. Nubeqa (darolutamide) will be expanded on the Pharmaceutical Benefits Scheme to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC). AAP Image/Mick Tsikas
Imagination is required to come up with novel methods of encouraging better health care among men, with only so many ways experts can say the same thing.
New research revealing that cost of living pressures have become a hurdle to Australians seeking regular medical check-ups is making that task a no-brainer.
